Atrial natriuretic peptide and C-type natriuretic peptide do not acutely inhibit the release of adrenocorticotropin from equine pituitary cells in vitro.

The research examines the effect of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) on the secretion of the corticotropin hormone (ACTH) in horse pituitary cells, concluding that these peptides do not inhibit ACTH secretion.

Research Objective and Background

• The research sought to determine whether atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) inhibit the secretion of adrenocorticotropin (ACTH) from horse pituitary cells. This is due to previous suggestions that ANP could be an inhibitor of ACTH secretion, but the evidence is not clear.

Research Methodology

• In order to mimic an environment closely resembling the one inside a horse’s body, the researchers used perifused equine pituitary cells in an in vitro settings.
• The corticotropin-releasing hormone at 20 picomolar (pM) and cortisol at either 0 or 100 nanomolar (nM) were continuously perifused, and 7 pulses of arginine vasopressin (AVP) at 10 nanomolar (nM) were applied every 5 minutes at 30-minute intervals.
• The introduction of ANP or CNP commenced just before the 3rd pulse of AVP and continued for 75 minutes.

Research Findings

• The experiment concluded that neither ANP nor CNP, with or without the presence of cortisol, had a significant impact on the ACTH secretory response to the AVP pulses. Therefore, these natriuretic peptides are likely not acting as rapid inhibitors of ACTH secretion in the pituitary of a horse.

Significance of the Study

• If the role of ANP and CNP in inhibiting ACTH were established, it could have potential implications for treatments involving hormonal activity. However, this research concludes that these peptides do not function as inhibitors to ACTH in horses, giving further physiological understanding of how these hormones function.